GLPBio

Myelopeptide-2 (MP-2)

Catalog No.: GP10114Purity:>98.00%Synonyms: H2N-Leu-Val-Val-Tyr-Pro-Trp-OH
COASDSData Sheet
Myelopeptide-2 (MP-2) is an immunomodulator derived from porcine bone marrow cell culture supernatant.

제품은 연구용으로만 사용됩니다. 인체에 사용할 수 없으며 환자에게 판매하지 않습니다.

Myelopeptide-2 (MP-2)
Cas No.: 137833-31-9
1mgIn Stock
$31.00
1
5mgIn Stock
$89.00
1
10mgIn Stock
$157.00
1
25mgIn Stock
$207.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

인용 문헌 (Citations)

현재 이 제품에 대한 인용 문헌이 없습니다. 아래는 GlpBio 제품을 인용한 주요 논문입니다.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

제품 설명 (Description)

Myelopeptide-2 (MP-2) is an immunomodulator derived from porcine bone marrow cell culture supernatant. Myelopeptide-2 restores the mitotic reactivity of human T lymphocytes suppressed by HL-60 leukemia cell conditioned medium or measles virus. Myelopeptide-2 can be used in studies on tumor immunosuppression recovery and antiviral immunotherapy[1-4].

In vitro, phytohemagglutinin-stimulated T lymphocytes were incubated with 100μg/mL Myelopeptide-2 and HL-60 cell conditioned medium for 72 hours. Myelopeptide-2 restored T lymphocyte proliferative response. Myelopeptide-2 restored CD3 and CD4 antigen expression and CD25-positive cell proportion[5]. T lymphocytes were treated with 10-25μg/mL Myelopeptide-2 for 18-24 hours. Myelopeptide-2 restored T lymphocyte cytotoxic activity against P-388 leukemia cells[6].

In vivo, urethane-induced BALB/c mice received 10μg/mouse Myelopeptide-2 by intraperitoneal injection daily for 4 days. Myelopeptide-2 reduced the number of spontaneous lung adenomas. Urethane-induced BALB/c mice received 100μg/mouse Myelopeptide-2 by intraperitoneal injection for 25 days. Myelopeptide-2 reduced animal mortality and delayed the first appearance time of lung tumors[7]. Female mice transplanted with Ca-755 cells, Lewis cells, or S180 cells received 0.5mg/kg Myelopeptide-2 by subcutaneous injection once daily for 5 times, or 1mg/kg or 2mg/kg every 96 hours for 2 times. Myelopeptide-2 inhibited transplanted tumor growth[8].

References:
[1] Petrov R. Myelopeptides: new immunoregulatory peptides. Allergy Proc. 1995 Jul-Aug;16(4):177-84.
[2] Sorokina NS, Starostina MV. Myelopeptides Reduce Morphine Tolerance in C57BL/6j Mice. Bull Exp Biol Med. 2021 Sep;171(5):623-626.
[3] Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, et al. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. J Immunother. 2006 May-Jun;29(3):306-12.
[4] Svirshchevskaya EV, Belevskaya RG, Roslavtzeva TA, et al. Influence of Myelopeptides on IL-1 and IL-2 Activities. Russ J Immunol. 1997 Apr;2(1):29-36.
[5] Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes suppression of T lymphocytes induced by human leukemia HL-60 cells. Immunol Lett. 1996 Jun;50(1-2):143-7.
[6] Khabarov SV, Gerasimova GK, Mikhailova AA, et al. Myelopeptide-2 Induces the Resistance of T-Lymphocytes to Tumor Suppression. Dokl Biol Sci. 2003;390:282-5.
[7] Mikhailova AA, Kirilina EA, Morozova OV, et al. Effect of Myelopeptide-2 on the Development of Spontaneous and Urethane-Induced Tumors in Mice. Bull Exp Biol Med. 2002 Jan;133(1):68-70.
[8] Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and Properties of the retro-Analogue of Myelopeptide MP-2. Russ J Bioorg Chem. 2005;31(3):210-5.

실험 프로토콜 (Protocol)

Cell experiment [1]:

Cell lines

 human peripheral blood T lymphocytes

Preparation Method

 PHA-stimulated human T lymphocytes were cultured with 10%(v/v) HL-60 cell conditioned medium as suppressive substance, and Myelopeptide-2 was added at 0.1-100μg/mL simultaneously with or after 1h/24h exposure to HL-60 CM for 72h; [3H]thymidine incorporation and flow cytometry for CD3, CD4, and CD25 were then measured.

Reaction Conditions

 0.1-100μg/mL; 72h

Applications

 Myelopeptide-2 abolished HL-60 CM suppression of PHA-induced T lymphocyte proliferative response in a dose-dependent manner. Myelopeptide-2 restored CD3- and CD4-positive cell proportions and CD3- and CD4-positive fluorescence intensity, restored CD25-positive cell proportion reduced by HL-60 CM.
Animal experiment [2]:

Animal models

 female mice (linear and hybrid, 18-20g body mass)

Preparation Method

Mice were transplanted with Ca-755 adenocarcinoma of mammary gland, Lewis lung adenocarcinoma, or S180 sarcoma cells (50mg per mouse) on day 0. Starting from day 3 after transplantation, mice were treated with Myelopeptide-2 dissolved in isotonic solution by subcutaneous injection according to two schemes: 0.5mg/kg five times at 24h intervals, or 1mg/kg or 2mg/kg two times at 96h interval. Control mice received isotonic solution. Tumor volumes were measured on days 7, 14, and 18 after transplantation for calculation of dynamics of growth inhibition (DGT).

Dosage form

0.5-2mg/kg; s.c.; five times at 24h intervals or two times at 96h interval

Applications

Myelopeptide-2 inhibited the growth of Ca-755 adenocarcinoma of mammary gland, Lewis lung adenocarcinoma, and S180 sarcoma in mice.
References:
[1] Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes suppression of T lymphocytes induced by human leukemia HL-60 cells. Immunol Lett. 1996 Jun;50(1-2):143-7.
[2] Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and Properties of the retro-Analogue of Myelopeptide MP-2. Russ J Bioorg Chem. 2005;31(3):210-5.

제품 문서 (Product Documents)

Purity:>98.00%Appearance:A solid
COASDSData Sheet

화학적 특성 (Chemical Properties)

CAS 번호
137833-31-9
동의어
H2N-Leu-Val-Val-Tyr-Pro-Trp-OH
SMILES
N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CC(C=CC=C4)=C4N3)C(O)=O)=O)=O)=O)=O)=O
분자식
C41H57N7O8
분자량
775.93
용해도
≥77.5mg/mL in DMSO
보관
Store at -20°C
일반 주의사항
제품의 용해도 데이터에 따라 적절한 용매를 선택하십시오. 조제 후에는 반복적인 동결·해동을 피할 수 있도록 저장 용액을 소분하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
배송 조건
평가용 샘플은 아이스팩과 함께 배송됩니다. 그 외 용량은 실온 배송되며, 요청 시 아이스팩과 함께 배송할 수 있습니다.

계산 도구 (Calculators)몰 농도 / 희석 / 분자량 / 단위 변환 / 생체 내 제형 / 용해도

g/mol

Reviews

Review for Myelopeptide-2 (MP-2)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%